1998
DOI: 10.2337/diacare.21.10.1699
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Domperidone on the Health-Related Quality of Life of Patients With Symptoms of Diabetic Gastroparesis

Abstract: Results suggest that patients with symptoms of diabetic gastroparesis experience notable HRQOL impairment and that symptomatic relief with domperidone is accompanied by improvements in HRQOL that can be sustained over 4 weeks of treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
44
0
5

Year Published

1999
1999
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 73 publications
(54 citation statements)
references
References 16 publications
5
44
0
5
Order By: Relevance
“…In the current study, the expression of sweet taste receptors in the duodenum, proximal jejunum, and mid-jejunum-very upper intestine-was increased by the administration of mosapride citrate but not by domperidone, which is also a prokinetic agent. This result corresponds to the observation that only mosapride citrate has the property of enhancing insulin sensitivity and glucose utilization in muscle, unlike domperidone and metoclopramide [4,42], whereas domperidone is effective for diabetic gastropathy as is mosapride citrate [5,43,44]. This enhancement of insulin sensitivity in muscle may be caused by GLP-1 which was increased by the administration of mosapride citrate.…”
Section: Discussionsupporting
confidence: 88%
“…In the current study, the expression of sweet taste receptors in the duodenum, proximal jejunum, and mid-jejunum-very upper intestine-was increased by the administration of mosapride citrate but not by domperidone, which is also a prokinetic agent. This result corresponds to the observation that only mosapride citrate has the property of enhancing insulin sensitivity and glucose utilization in muscle, unlike domperidone and metoclopramide [4,42], whereas domperidone is effective for diabetic gastropathy as is mosapride citrate [5,43,44]. This enhancement of insulin sensitivity in muscle may be caused by GLP-1 which was increased by the administration of mosapride citrate.…”
Section: Discussionsupporting
confidence: 88%
“…GI autonomic neuropathy GI symptoms are relatively common among patients with diabetes and often reflect diabetic GI autonomic neuropathy (7,122 Esophageal dysfunction results at least in part from vagal neuropathy (123); symptoms include heartburn and dysphagia for solids. Via the use of radioisotopic techniques that quantify gastric emptying, it appears that ϳ50% of patients with longstanding diabetes have delayed gastric emptying (gastroparesis) Vinik and Associates (124).…”
Section: Other Autonomic Neuropathiesmentioning
confidence: 99%
“…Subscale scores range from 0 to 100, with higher scores reflecting better health status. The SF-36 subscale scores have excellent reliability and good construct validity in the general population and chronic disease populations [36], including patients with GI disease [5,14,28,30,[37][38][39].…”
Section: Health-related Quality Of Life Measuresmentioning
confidence: 99%
“…Only limited information is available on the psychometric qualities of many of these measures [5]. Clinical trials comparing treatments for upper GI disorders have often used daily diaries covering key symptoms, such as heartburn in GERD [4,10,[21][22][23][24][25][26] or have used clinical symptom scales assembled to cover the relevant symptoms associated with dyspepsia [12,16,17,27] or gastroparesis [19,20,[28][29][30][31]. Frequently, these clinical assessment measures are not evaluated for reliability and validity; thus it is unknown whether they can be justified as clinical endpoints.…”
Section: Introductionmentioning
confidence: 99%